Inhaled Insulin is Dead. Long Live Inhaled Insulin
In early March, Eli Lilly became the third major pharmaceutical company to scupper its inhaled insulin program. Almost immediately the blogosphere began nailing inhaled insulin's coffin shut. IN VIVO thinks it's still too soon to deliver a eulogy. One company, MannKind, continues undaunted, despite the setbacks for it's competitors, hoping to bring its inhaled insulin to market by 2010. Meantime, specialty pharmaceutical companies or glucose monitoring testing outfits might be interested in the inhaled programs spurned by Big Pharma, but only for the right price.
You may also be interested in...
Does the recent rash of follow-on public offerings mean biotech IPOs are around the corner? Recent financings provide reason to think it's possible.
If you think this is a bad time to try to get a loan, try selling a type 2 diabetes research project to a Big Pharma company. Diabetes, simultaneously one of the largest yet most under-treated prescription drug markets in the world, is suddenly out of favor with Big Pharma business development executives. And the reason isn't hard to spot: the belief that regulatory hurdles have fundamentally changed the business case for drug development in the category.
The clinical community and the medical device industry are finally turning their attention to the majority of patients with diabetes: the type 2s. They're an underserved group in a potential market that dwarfs that of type 1 diabetes. Health Advances LLC believes that the next disruptive technology in diabetes management will come in the form of lower-cost, easy-to-use insulin pumps for the masses. And there are at least 16 such pumps in development. (See also the sidebar, CeQur: Conforming to the Lifesyle of the Type 2).